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Abstract
Leprosy is a chronic infectious disease caused by the intracellular pathogen 
Mycobacterium leprae. The disease may present different clinical forms depending 
on the immunological status of the host. M. leprae may infect macrophages and 
Schwann cells, and recent studies have demonstrated that macrophages are funda-
mental cells for determining the outcome of the disease. Skin lesions from patients 
with the paucibacillary form of the disease present a predominance of macrophages 
with a pro-inflammatory phenotype (M1), whereas skin lesions of multibacillary 
patients present a predominance of anti-inflammatory macrophages (M2). More 
recently, it was shown that autophagy is responsible for the control of bacillary 
load in paucibacillary macrophages and that the blockade of autophagy is involved 
in the onset of acute inflammatory reactional episodes in multibacillary cells. So, 
strategies that aim to induce autophagy in infected macrophages are promising 
not only to improve the efficacy of multidrug therapy (MDT) but also to avoid the 
occurrence of reactional episodes that are responsible for the disabilities observed 
in leprosy patients.
Keywords: macrophages, leprosy, innate immunity, scavenger receptors, autophagy
1. Introduction
Macrophages are highly plastic and heterogeneous in several aspects, present-
ing a spectrum of distinct phenotypes according to the microenvironment [1–3]. 
During mycobacterial infection, its membrane components have the ability to 
induce polarization and interaction with this type of cell [4]. The cell wall of M. 
leprae consists of lipids and contains large amounts of phthiocerol dimycocerosate 
and phenolic glycolipid-1 (PGL-1) [5, 6]. PGL-1 has been identified as an important 
antigen and virulence factor, which has also been shown to be a promising diagnos-
tic molecule by inducing the production of IgM class antibodies [7, 8]. Interestingly, 
the presence of lipids and sugars in the cell wall also induces an increase in phago-
cytosis [9], both by macrophages and by other cell types. Besides that, the presence 
of M. leprae-PGL-1 interacting with resident macrophages is able to lead to the 
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production of nitric oxide, thus causing peripheral nerve damage characteristic 
of patients with leprosy [10]. Other studies have shown the ability of M. leprae to 
induce the production of oxidative mediators and their products, peroxynitrite and 
nitrotyrosine [11–14].
Studies have demonstrated the ability of M. leprae to interact with a range 
of scavenger receptors of macrophages culminating in a tolerogenic response 
profile. The scavenger receptors are membrane receptors whose main function 
is the removal of molecules and cellular debris from the body, binding through a 
variety of polyanions, leading to phagocytosis of the target, being found in several 
cell types such as macrophages [15]. The ability of M. leprae to interact with the 
CD163 receptor, a scavenger receptor, which, during this interaction, can act as a 
co-receptor for M. leprae entry in macrophages, has been described [16]. It is known 
that activation of this receptor is related to the activation of the transcription factor 
nuclear factor erythroid 2-related factor 2 (NRF2), leading to the synthesis and 
increase of the activity of the enzyme heme oxygenase-1 (HO-1), which, through 
anti-inflammatory and antioxidant pathways, releases interleukin (IL)-10 and 
generates carbon monoxide, contributing to the polarization of these cells [17–19]. 
Bonilla and colleagues [20] demonstrated that autophagy, a mechanism of meta-
bolic control, regulates the expression of scavenger receptors macrophage receptor 
with collagenous structure (MARCO) and scavenger receptor type A (SRA-I) that 
increase phagocytosis and NRF2 activity during Bacillus Calmette-Guérin (BCG) or 
M. tuberculosis (H37Rv) infection.
M. leprae is able to induce macrophage SRA-I and CD36 expression [6] that 
contributes to the uptake of lipids, culminating in an increase in the uptake and 
accumulation of oxidized lipids within the macrophages, leading to a foamy cell 
phenotype, associated with an inhibition of the pro-inflammatory response with 
downregulation of major histocompatibility complex (MHC) II and toll-like recep-
tor (TLR) 2 [21, 22]. Dendritic cell-specific intercellular adhesion molecule-3-grab-
bing non-integrin (DC-SIGN or CD209) is another scavenger receptor present in 
macrophages that interacts with M. leprae, and it is involved in the phagocytosis of 
the bacilli [23, 24]. Other receptors have been described with great importance in 
the initial interaction and polarization of the response of macrophages to bacteria. 
It has recently been observed that M. leprae is able to activate innate receptors such 
as TLR4 [25], through PGL-1 that induces the irregular production of interferon 
(IFN)-β, chemokine (C-X-C motif) ligand (CXCL)-10/interferon gamma-induced 
protein 10 (IP-10), and inducible nitric oxide synthase (iNOS), thus decreasing the 
production and activation via tumor necrosis factor (TNF) [26].
The persistence of M. leprae infection depends on the type of the host immune 
response. Macrophages are crucial modulators of innate and adaptive immune 
responses are the main cell types directly infected by the bacillus, and can lead to 
different immune responses. The initial interaction of the macrophage with M. lep-
rae is essential for the polarization of the response toward a susceptible phenotype, 
favoring the survival of the bacilli. In this way, studies that elucidate this contact 
may favor the protective response against infection, thus contributing to strategies 
of control of the disease.
2. Macrophage polarization and M. leprae infection
Macrophages are specialized cell types present in most mammalian tissue. 
Recently, many studies have been highlighting the “general” and “tissue-specific” 
functions of macrophages, including their roles in systemic metabolism, fibrosis, 
development, cancer, and tissue homeostasis [27]. However, these cells are best 
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known for their role in the innate immunity, which was first addressed by Ilya 
Metchnikoff in 1884 in his work describing the “phagocytes” [28]. Several subsets 
of macrophages were described in different pathological conditions and tissues of 
humans and mice based on their phenotype and biological functions [1, 29–31]. 
Despite their high plasticity, macrophages are classically described in two main 
functionally distinct phenotypes—classically activated or inflammatory macro-
phages (M1) and alternatively activated or healing macrophages (M2)—reflecting 
the T helper type (Th) 1 and Th2 response profiles [2, 3, 30].
In summary, M1 macrophages are induced by lipopolysaccharide and IFN-γ in a 
pro-inflammatory environment promoting a microbicidal and inflammatory phe-
notype, while polarization to M2 macrophages, induced in response to IL-4 (M2a), 
immune complexes (M2b) or IL-13 and IL-10 (M2c), is rather anti-inflammatory 
and associated with healing and tumor progression. In addition, granulocyte 
and macrophage colony-stimulating factor (GM-CSF) and macrophage colony-
stimulating factor (M-CSF) induce the differentiation of macrophages into, respec-
tively, M1 and M2 phenotypes [2, 3, 32, 33]. Previously, it was demonstrated that 
macrophages differentiated with GM-CSF or M-CSF were able to phagocytose M. 
leprae [34]. Despite this, only GM-CSF-differentiated M1 cells were able to stimu-
late T cells to produce IFN-γ, after treatment of the macrophages with IFN-γ and 
CD40 ligand; furthermore, this treatment induced expression of major membrane 
protein (MMP)-II on the macrophage cell surface, suggesting its ability to process 
the phagocytosed bacteria [34]. In addition, M. leprae was able to induce IL-10 
production in M-CSF-differentiated M2 cells, but not in GM-CSF-differentiated M1 
macrophages.
In 2016, the protein jagged 1 (JAG1) was identified as a potential regulator of 
macrophage polarization in leprosy [35]. While unstimulated endothelial cells lead 
to M2 macrophage polarization, in the presence of IFN-γ, endothelial cells induce 
the differentiation to M1 macrophages. JAG1 is preferentially expressed in the vas-
cular endothelium in skin lesions of paucibacillary tuberculoid patients, stimulating 
the differentiation of M1 antimicrobial macrophages by the IFN-γ-JAG1 axis [35].
Due to increased systemic pro-inflammatory mediators, a higher frequency of 
apoptosis was described in paucibacillary tuberculoid patients [36]. Curiously, the 
phagocytosis of apoptotic cells in the presence of M. leprae induces a shift from M1 
to M2 phenotype in GM-CSF-differentiated macrophages with increased expres-
sion of scavenger receptors as SRA-I, production of IL-10 and transforming growth 
factor beta (TGF-β) anti-inflammatory cytokines, and decreased levels of pro-
inflammatory IL-15 and IL-6 by a mechanism mediated by arginase [37] (Figure 1). 
Based on those results, it was suggested that in paucibacillary tuberculoid skin 
lesions, the phagocytosis of apoptotic cells would induce an M2 phenotype in some 
macrophages, explaining the persistence of the disease besides the ability to mount 
an effective cellular immune response to M. leprae infection [37].
Analysis of paucibacillary tuberculoid and reversal reaction (an acute inflammatory 
clinical condition associated with increased levels of IFN-γ in leprosy patients) patients’ 
skin lesions demonstrated that macrophage subtypes with microbicidal and homeo-
static functions are spatially distributed in tuberculoid granulomas according to the 
specific microenvironments [38]. The center of the tuberculoid granulomas appears to 
be populated by pro-inflammatory CD68+ CD163− M1 macrophages, responsible for 
containing the infection, while the periphery is composed of anti-inflammatory CD68+ 
CD163+ M2 macrophages, tasked with limiting tissue damage caused by the M1 macro-
phage antimicrobial activity [39]. Accordingly, Montoya and colleagues [22] proposed 
two different macrophage functional programs for the polar clinical forms of leprosy. 
They suggested that in tuberculoid paucibacillary patients, IL-15 induces the vitamin 
D-mediated antimicrobial program in the macrophages, resulting in killing of the 
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mycobacteria, while in multibacillary lepromatous patients, the higher levels of IL-10 
would induce the phagocytic pathway by increasing the expression of CD209 and scav-
enger receptors as CD163 in the macrophage cell surface, resulting in phagocytosis of 
M. leprae and oxidized low-density lipoproteins (LDL) favoring the formation of foam 
cells and persistence of the infection [22]. In addition, antimicrobial M1 macrophages 
differentiated with IL-15 could be repolarized into the phagocytic M2 phenotype after 
treatment with IL-10, while phagocytic IL-10-differentiated M2 macrophages could 
only be repolarized into the M1 phenotype after co-stimulation with TLR2/1 ligand and 
IFN-γ or TLR2/1 ligand and anti-IL-10-neutralizing antibodies, but not IL-15 or IFN-γ 
alone, suggesting that production IL-10 by M2 macrophages might create a barrier for 
M1 reprogramming [39].
M. leprae infection of IL-10-differentiated M2 cells results in induction of 
type I IFN and suppression of the vitamin D directed pathway, suggesting that 
M. leprae evades the intrinsic capacity of human cells to activate the vitamin 
Figure 1. 
Macrophage plasticity in tuberculoid skin cells. M1 phenotype prevails in tuberculoid cells. The pro-
inflammatory cytokines present in the tissue may contribute to increased host cell apoptosis, and the removal of 
the apoptotic cells may contribute to changes in macrophage plasticity. M1 macrophages that uptake M. leprae 
and apoptotic cells have an increase in the percentage of M2 markers CD163 and SRA-I that is dependent 
on arginase production, since the arginase inhibitor N-hydroxy-nor-L-arginine (nor-NOHA) blocks these 
phenotype changes. In addition, the stimuli with M. leprae and apoptotic cells induce an increase in the 
production of IL-10 and TGF-β that contributes for inducing the secretion of IL-4 and IL-13 by Th2 cells that 
sustain some M2 cells in tuberculoid lesions.
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D-mediated antimicrobial pathway via the induction of type I IFN [40]. Although 
previous studies have demonstrated the activation of antimicrobial pathways in 
IL-15-differentiated macrophages, there is no study demonstrating how vitamin D 
status modulates IL-15-differentiated macrophage phenotype and function. More 
recently, it was demonstrated that the presence of vitamin D during macrophage 
differentiation bestows the capacity of human macrophages to mount an antimicro-
bial response against M. leprae [41]. However, more studies are needed to evaluate if 
the plasma levels of vitamin D could be a predictor of the outcome of the disease.
Several studies demonstrated the predominance of M2 markers like CD68, 
CD209, CD163, SRA-I, HO-1, arginase-1, IL-10, IL-13, TGF-β, and basic fibroblast 
growth factor in multibacillary lepromatous patients’ skin lesion macrophages [16, 
22, 37, 42–44]. In the same way, CD163, the hemoglobin (Hb) scavenger receptor, 
might contribute to the polarization of multibacillary lepromatous macrophages to 
an anti-inflammatory profile by increasing the expression of indoleamine 2,3-diox-
ygenase (IDO) and IL-10, in addition to increasing the internalization of M. leprae 
and iron, contributing to the mycobacterial persistence [16, 45]. The increase in the 
internalization of Hb-haptoglobin (Hp) complex by CD163 contributes to the acti-
vation of the enzyme HO-1 via IL-10 [46]. de Mattos Barbosa and colleagues [42] 
proposed that M. leprae-infected skin macrophages would increase the acquisition 
of iron both by transferrin and heme-bound, via transferrin receptor 1 and CD163, 
activating the enzyme HO-1 that catalyzes heme into carbon monoxide, biliverdin, 
and free iron, increasing the intracellular iron pool and the iron storage in the 
protein ferritin (Ft), due to a reduction in expression of the sole iron exporter, 
ferroportin 1 (Fpn-1) [42] (Figure 2). Iron retention via Ft and reduced secretion 
of iron by Fpn-1 are classical traits of microbicidal inflammatory M1 macrophages, 
while tissue repair-associated M2 are characterized by enhanced HO-1-mediated 
heme catalysis and increased iron exportation via Fpn-1 [46]. Even though there is 
a prevalence of M1 or M2 markers in the polar clinical forms of leprosy, skin lesion 
macrophages present themselves in a spectrum of heterogeneous phenotypes shar-
ing characteristics of both subtypes, and more than one specific population can be 
present at the same time [38, 42, 47].
A different subset of macrophages, known as M4, was described in skin lesions 
from lepromatous patients. M4 macrophages in lepromatous skin lesions were 
described as CD68-positive cells that express myeloid-related protein 8 (MRP8) 
and matrix metalloproteinase (MMP)-7 [48]. This particular subset of macro-
phages is differentiated with the platelet chemokine CXCL4 and is mostly related 
to the formation of foamy cells present on atherosclerotic lesions due to increased 
expression of LDL receptors. Macrophages differentiated with this chemokine 
present a functionally distinct phenotype characterized by increased expression 
of CD206, CD68, IL-6, TNF, MRP8, MMP7, and MMP12, suppressed phagocytic 
capacity, and the complete lack of CD163 accompanied by the inability to induce 
HO-1 in response to Hb-Hp complexes, which is irreversible even after removal of 
CXCL4 and stimulation with M-CSF or IL-10 [32, 48, 49]. Expression of IL-6 and 
TNF, cytokines associated with the promotion of microbicidal M1 macrophages 
responses, was increased on skin lesions of paucibacillary tuberculoid patients 
[48]. Additionally, in vitro exposure to M. leprae or PGL-1 impairs the capacity of 
healthy donor’s monocytes to differentiate to M1 macrophages, reducing the cell 
surface expression of M1 markers and the production of M1-associated chemo-
kines and cytokines [50]. It was hypothesized that previous contact with M. leprae 
might limit the functional capacity of monocytes, reducing the ability to mount 
an effective immune response in a secondary contact [50]. Together, these data 
support the idea that an anti-inflammatory regenerative environment restrictive of 
microbicidal response is promoted in lepromatous patient’s skin lesions, leading to 
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differentiation of a heterogeneous subset of highly phagocytic iron and lipid-loaded 
foamy macrophages that create an ideal environment for survival and vast propaga-
tion of the M. leprae infection and consequently the increase in the number of skin 
lesion in this pole of the disease [16, 22, 37, 42–44, 48].
3. The role of macrophages in the immune response to M. leprae
One of the most crucial steps in a human innate immune response is how the 
host cells recognize a microbial pathogen. The TLR family has a vital role in the 
Figure 2. 
Lepromatous leprosy macrophage iron metabolism. Skin lesion macrophages of lepromatous patients present 
high expression of M2 markers as CD163, a scavenger receptor that recognizes hemoglobin-haptoglobin 
(Hb-Hp) complex and was previously implied in M. leprae internalization. The heme molecules are degraded 
by heme oxygenase-1 (HO-1) that catalyzes heme in free iron, carbon monoxide (CO), and biliverdin that is 
converted to bilirubin by the enzyme biliverdin reductase; these are classically upregulated in M2 macrophages. 
Transferrin receptor 1 (TfR1) is also increased in lepromatous macrophages. This receptor recognizes 
iron-bound transferrin, which is endocytosed, and the iron is later liberated to the cytoplasm. Lepromatous 
macrophages also present a lower expression of ferroportin 1, the iron cellular exporter, characteristic from 
M1 macrophages, contributing to increasing the cellular iron pool. The free iron present in the cytoplasm is 
quickly stored in the form of ferritin but can also be available for M. leprae use and increased growth in the 
phagosomes, as observed in this clinical form. Natural resistance-associated macrophage protein 1 (NRAMP1) 
is also increased in lepromatous macrophages, but its role in M. leprae-infected cells is still to be determined.
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mycobacterial recognition and subsequently induction of antimicrobial defenses 
and adaptive immune response [51]. Recognition of M. leprae pathogen-associated 
molecular patterns (PAMPs) occurs through the TLR2/1 heterodimer to the tri-acyl-
ated lipopeptides, leading to the differentiation of monocytes into macrophages and 
dendritic cells and triggering the production of TNF as part of an acute inflamma-
tory response [52]. The tissue expression of TLRs correlated with the immunologi-
cal spectrum of the disease, once both TLR1 and TLR2 were prominently observed 
in the self-limited tuberculoid lesions when compared to the disseminated leproma-
tous lesions [53]. Another pattern recognition receptor (PRR) involved in M. leprae 
detection is nucleotide-binding oligomerization domain-containing 2 (NOD2). 
Human NOD2 receptor recognizes structurally unique muramyl dipeptides from 
M. leprae, triggering an IL-32-mediated innate immune response that induces the 
differentiation of monocytes into dendritic cells [54, 55]. Interestingly, activation 
of monocytes via NOD2 agonist was more efficient in the induction of dendritic cell 
differentiation than TLR2/1 ligand treatment [54].
The activation of PRR can induce the antimicrobial autophagy pathway, a 
biological process regulated by multiple specialized proteins known as autophagy-
related proteins (ATG), and can be started in response to various cellular stresses 
and signals such as nutrient withdrawal, growth factor deprivation, and cytokine 
stimulation and also by pathogen infection [47]. In addition to the role of autophagy 
in the elimination of potentially toxic protein aggregates and in the prevention of 
neurodegeneration [56], autophagy plays a key role in the host’s response to myco-
bacterial infection, because it is able to reverse the blockade of phagosome matura-
tion, inhibiting the intracellular survival of the pathogen [57]. It has been shown 
that autophagy is an important innate mechanism associated with leprosy immuno-
pathogenesis [58]. Recently, it was demonstrated that autophagy enhances the ability 
of M. leprae-infected Langerhans cells to present antigens to CD1a T cells [59].
As mentioned earlier, the paucibacillary tuberculoid skin macrophages activate 
the vitamin D pathway and produce antimicrobial peptides that could be involved 
in autophagy induction. In addition, Silva and colleagues [58] demonstrated that 
autophagy is differentially regulated between leprosy polar forms. In paucibacillary 
tuberculoid skin lesion macrophages, IFN-γ/beclin 1-induced autophagy contrib-
utes for M. leprae control, whereas in lepromatous macrophages B cell lymphoma 2 
(BCL2)-mediated blockade of beclin 1 autophagic pathway promotes mycobacterial 
persistence [58]. Indeed, the M. leprae can take advantage of host antiviral protein 
2′-5′-oligoadenylate synthetase like (OASL) to inhibit autophagy and promote its 
own survival through a stimulator of interferon genes (STING)-mediated type I 
IFN response [60]. Furthermore, the autophagy levels were restored in leproma-
tous patients undergoing reversal reaction episodes [57]. More recently, de Mattos 
Barbosa et al. [61] elegantly demonstrated a role for autophagy in the development 
of reversal reaction. This study showed a downregulation of autophagy associ-
ated with inflammasome activation in skin lesion macrophages of multibacillary 
leprosy patients who developed reversal reaction episodes in the future. Thus, 
the autophagic pathway is a key factor in multibacillary leprosy patients to avoid 
exacerbated inflammasome activation and the onset of reversal reaction. A newly 
published study showed that Th17-derived cytokine IL-26 has a direct bind capac-
ity and antimicrobial effect against mycobacteria in cell-free cultures [62]. In M. 
leprae-infected macrophages, IL-26 treatment was associated with autophagy 
induction via STING (probably due to its ability to bind DNA) as well targeting of 
mycobacteria to lysosomal compartments [62]. Curiously, it has been shown in M. 
tuberculosis-infected macrophages that the cytosolic DNA sensor cyclic GMP-AMP 
synthase (cGAS), an upstream receptor to STING, controls both pro-mycobacterial 
type I IFN production and the activation of antimycobacterial selective autophagy 
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Figure 3. 
Targeting M. leprae to autophagy (xenophagy) in macrophages of leprosy patients. (Left) After phagocytosis, 
M. leprae causes phagosome maturation arrest and phagosomal permeabilization through the bacterial 
ESX-1 secretion system, which allows the detection of extracellular mycobacterial DNA by the cGAS/STING-
sensing cytosolic surveillance pathway that licenses the ubiquitination of mycobacteria and recognition by 
the ubiquitin-binding autophagy adaptors p62 and NBR1 (and probably NDP52 and OPTN), which finally 
interact with LC3, allowing the mycobacterial phagosome to become sequestered within an autophagosome. 
The autophagosome-sequestered phagosome maturates in a degradative autophagolysosome (which also 
contains antimicrobial peptides) by fusing with a lysosome and leads to the pathogen destruction and antigen 
presentation. Other molecules such as TBK1, IRF3, DRAM1, UBQLN1, PARKIN, and SMURF1 might be 
also involved in this process. Microbial invasion can be also detected and targeted to autophagy pathway by 
galectins that act as a receptor for vacuole-damaging pathogens or by TRIM-mediated precision autophagy, 
which can directly recognize the bacterial target without required intermediary autophagic tags such as 
ubiquitin and galectins. TRIMs and galectins also cooperate during selective autophagy. TRIM proteins use 
galectins and ubiquitins to detect and tag damaged mycobacteria-containing phagosomes and promote the 
assembly of autophagic machinery via MTOR inhibition and AMPK activation. IFN-γ-mediated autophagy 
requires IRGM, which interacts with ULK1 and BECN1 and dissociates BCL2 from BECN1-PIK3C3 complex, 
thus governing the assembly of autophagy initiation complexes that will further promote the incorporation of 
mycobacterial phagosomes into autophagosomes. Autophagy initiation step is amplified by the detection of M. 
leprae-derived MDP by NOD2, which enhances NOD2-IRGM interaction and induces IRGM ubiquitination. 
IRGM can also activate BECN1 via AMPK induction. IFN-γ can also induce autophagy through the IL-15/
VD3/cathelicidin pathway. IL-26 is reported to activate autophagy via STING. M. leprae can dampen 
autophagy initiation by increasing the BCL2 levels and its interaction with BECN1 or by induction of type I 
IFN signaling pathway (which includes OASL) that inhibits the VD3-dependent autophagy. M. leprae can 
also hamper the autophagy maturation step by an unknown mechanism, which might involve the BECN1-
BCL2 association. Autophagy activating pathways are prominently observed in tuberculoid macrophages, 
whereas autophagy inhibition processes are predominantly found in lepromatous macrophages. (Right) Another 
possible pathway is that right after phagocytosis, M. leprae is incorporated into phagolysosomes but avoids 
lysosomal degradation via translocation from the phagolysosomes to the cytosol by using the ESX-1 secretion 
system. The M. leprae cytosolic entry is followed by ubiquitin-mediated autophagy recognition and degradation 
into mature autolysosomes. Green arrows indicate steps activating autophagy. Red arrows and inhibition bars 
represent steps inhibiting autophagy.
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pathway, which can be uncoupled from intracellular immune responses mediated 
by NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome 
activation [63–65].
Galectins are a family of β-galactoside-binding cytosolic lectins that monitors 
endosomal and lysosomal integrity. These danger receptors can detect bacterial 
invasion by detecting unusual exposure of glycans to the cytosol and activate 
antibacterial autophagy [66–68]. Immunohistochemistry analysis of leprosy lesions 
revealed a higher expression of galectin-3 protein on lepromatous macrophages 
than tuberculoid cells. The increased galectin-3 expression in lepromatous cells was 
associated with the reduction of dendritic cell differentiation and T-cell antigen 
presentation [69]. Interestingly, galectin-3 was associated with both bacterial 
control and survival, as well as autophagy activation and inhibition [66, 68], 
whereas galectin-8 was related to antibacterial autophagy activation [67, 68]. The 
underlying cellular mechanisms of target M. leprae as an autophagic cargo destina-
tion in human macrophages are still not fully understood; some of them displayed 
in Figure 3 are insights from M. tuberculosis infection model.
Although the innate activation of macrophages orchestrates antimicrobial 
responses that contribute to host defense against intracellular pathogens such as M. 
leprae, those responses have been also implicated in the initiation of nerve damage 
in leprosy. The axonal damage is not directly mediated by M. leprae itself, but by 
M. leprae-specific PGL-1 induction of nitric oxide synthase in infected macro-
phages, which leads to axon damage by injuring their mitochondria and inducing 
demyelination [10]. Taken together, these findings illustrate the plasticity of human 
macrophages and how they deploy different strategies to fight against mycobacte-
rial infections. Most of the time, these approaches begin with microbe sensing and 
culminate in the targeting of the pathogen for destruction in the autolysosomal 
pathway (Figure 3), the tuberculoid leprosy macrophages being more efficient than 
the lepromatous ones in these processes. Hence macrophages are essential compo-
nents of mammalian tissues in which they perform a variety of biologic functions; 
understanding their difference is an essential step toward the development of innate 
immune countermeasures.
4. Macrophage autophagy as a target for the control of the disease
Leprosy remains a major global problem. Early detection of cases and immediate 
treatment with multidrug therapy (MDT) remain the main intervention strategies 
[70]. Despite the effectiveness of MDT in controlling the polar forms of the disease, 
limitations in terms of persistent activity in paucibacillary patients, in combination 
with the persistence of live and/or dead bacilli in multibacillary patients, have been 
observed, which has repercussions on the frequency of relapses and reactional 
episodes after treatment [71, 72]. Recent studies have demonstrated that autophagy 
is an important molecular mechanism for controlling the viability of mycobacteria 
in the host cell and of the bacillary load in patients with leprosy [58–60]. Autophagy 
can be induced by oxidative stress or by an infectious agent and is closely associated 
with the immune response and host defense [73, 74]. In addition to its homeostatic 
role, the autophagic degradation pathway is involved in several human diseases, 
including metabolic disorders, neurodegenerative diseases, cancer, and infectious 
diseases. Given these observations, pharmacological approaches to regulate posi-
tively or negatively this pathway are receiving considerable attention. For example, 
positive regulation of autophagy may be of therapeutic benefit in certain neuro-
degenerative diseases (e.g., Huntington’s disease), while inhibition of autophagy is 
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being investigated as a strategy for treatment of some cancers [75, 76]. The molecu-
lar regulators interconnecting autophagy and apoptosis, including BCL2, BCL2-
associated X protein (BAX), and beclin 1, have been suggested to act as switching 
points that are critical for the outcome of tumor cells, and lysosomes have been 
reported to initiate the cell death pathway in autophagic cells [77, 78]. Regarding 
leprosy, it was observed that in skin cells of patients with the lepromatous form of 
the disease there is a blockade of the autophagic flux that can be attributed to the 
increased expression of the antiapoptotic protein BCL2, which inhibits autophagy 
mediated by beclin 1 [58]. Blockade of the autophagic machinery in lepromatous 
cells may contribute to the persistence of mycobacteria in host cells. Genetic studies 
on leprosy have shown that several polymorphisms in genes associated with the 
control of autophagic pathways such as IFN, immunity-related GTPase family 
M protein (IRGM), NOD, and TLR play a prominent role in susceptibility to the 
disease, thus demonstrating the importance of understanding, inducing, and 
controlling this biological process in leprosy [79–85].
When the initial studies aiming at induction of autophagy were conducted, 
the only known drug capable of inducing autophagy chronically was rapamycin. 
However, the adverse effects of rapamycin (which were not associated with 
the induction of autophagy) made this drug unattractive to use. Several drugs 
and nutritional supplements can induce autophagy, such as verapamil, statins, 
metformin, resveratrol, vitamin D, and omega 3 [86]. Although it is not known 
whether these agents exert their beneficial clinical effects through the induction 
of autophagy or other pathways, there is a considerable overlap between diseases 
occurring in an environment of poor autophagy and diseases that respond to drugs 
that may induce autophagy. With regard to infectious diseases, there are limited 
data on the usefulness of autophagy-inducing pharmaceutical agents as potential 
therapeutics against human pathogens. Drug screening studies that aim to identify 
molecules with pro-autophagic effects have been performed, and promising results 
demonstrated a pro-autophagic effect of drugs capable of inhibiting the growth of 
M. tuberculosis in human macrophages in vitro [87–89]. In addition, the antibiotics 
isoniazid and pyrazinamide, two first-line cocktail drugs used to treat tuberculosis, 
exert their antimycobacterial activity through autophagy [90]. The treatment with 
statins, drugs that inhibit cholesterol synthesis, reduces the bacillary load of M. 
tuberculosis in human macrophages and mice by increasing autophagy and phago-
some maturation [91]. Furthermore, statins also have an antimicrobial effect against 
M. leprae and potentiate the antimycobacterial effect of rifampicin, a first-line 
cocktail drug used in leprosy treatment [92]. Vitamin D3, which activates autoph-
agy, has been successfully used in the treatment of patients with tuberculosis and 
could be one of the components of an ideal treatment for leprosy and other chronic 
infectious diseases in which the cellular immune response is deregulated [93–96].
Activation of autophagy by verapamil has been demonstrated by several groups. 
Initial studies evaluating the effect of verapamil and its analogs on macrophages 
infected with M. tuberculosis showed an association between the induction of 
autophagy and inhibition of intracellular replication of mycobacteria, and one of 
the structural analogs had an additive effect on the inhibitory antimicrobial activity 
of isoniazid and rifampicin [97, 98]. Metformin is an antidiabetic of the biguanide 
class. Mechanisms of autophagy induction by metformin are known, but no rela-
tionship with infectious processes caused by mycobacteria has been described so far. 
Similarly, resveratrol has also been studied for its autophagy-inducing role, and no 
studies in the literature have been found correlating with the mycobactericidal role.
Together, these data show the importance of autophagy in the pathogenesis of 
leprosy, contributing to a better understanding of the mechanisms of mycobacte-
rial control associated with the lepromatous and tuberculoid leprosy poles, which 
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may lead to the establishment of new targets and therapeutic strategies to control 
leprosy. Moreover, the identification of autophagy as an important factor during 
the establishment of resistant and susceptible forms of the disease opens the door 
for the development of new therapeutic strategies of disease control through the 
modulation of autophagy.
5. Conclusion
Considering the aspects observed during the course of this chapter, macro-
phages have a crucial role in inducing the immune response to M. leprae, and 
their uptake capacity, phagocytosis, and microbicidal activity may depend 
on the microenvironment. Macrophages, after the interacting with either the 
bacilli or its wall components, are able to induce oxidative stress [10–14] and to 
induce various receptors as scavenger receptors [6, 16, 23, 24, 34, 42–44] and 
PRR [53–55, 69], leading to the polarization of their response. In an anti-inflam-
matory profile (M2), this cell induces increased uptake of lipids [21, 22] and 
Hb-haptoglobin [16, 42], which aid the growth of M. leprae by the activation of 
the enzymes IDO [42, 45], HO-1 [42] and arginase [37]. On the other hand, in a 
pro-inflammatory and microbicidal profile (M1), the macrophage produces TNF 
[26, 48], IL-6 [37, 48, 49], and IL-15 [22, 37, 39] besides being able to stimulate T 
cells to produce IFN-γ [34]. In addition, these M1 macrophages induce autophagy 
[57, 58], an important process of homeostatic regulation recently described with 
the immunological role [56], which acts on infection control. Several drugs have 
been described as autophagy inducers and have been studied as treatment for 
neurodegenerative diseases [76] and to control of M. tuberculosis infection [89]. 
Autophagy-inducing drugs are promising targets as adjuvants to MDT.
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